THERF - FDA lab inspection OK

This is good, FDA has inspected the mainland China facility (WuXi Biologics) where ibalizumab will be manufactured from July 17 through August 2 and found no major issues, just some follow-up actions WuXi expects to complete within three months, which should not impact the BLA review timeline of ibalizumab.

Removes one of the possible reasons for non-approval of ibalizumab.

http://theratech.com/sites/default/files/news_release_en/nr-…

WuXi press release: http://www.wuxibiologics.com/the-u-s-fda-completed-pre-licen…